Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein
about
In Hot Pursuit of the First Vaccine Against Respiratory Syncytial VirusA novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent modelsEnzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.Mucosal vaccines against respiratory syncytial virusImpaired immune response to vaccination against infection with human respiratory syncytial virus at advanced ageSeroprevalence of respiratory syncytial virus IgG among healthy young adults in basic training for the Republic of Korea Air ForceCurrent concepts and progress in RSV vaccine development.Age-related differences in polyfunctional T cell responses.Protective and dysregulated T cell immunity in RSV infectionRespiratory syncytial virus (RSV) infection in elderly mice results in altered antiviral gene expression and enhanced pathologyMucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom.Development of Acquired Immunity following Repeated Respiratory Syncytial Virus Infections in Cotton Rats.Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.Translational sciences approach to RSV vaccine development.Novel therapies and vaccines against the human respiratory syncytial virus.Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection.The Human Immune Response to Respiratory Syncytial Virus Infection.Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.An in vitro model to study immune responses of human peripheral blood mononuclear cells to human respiratory syncytial virus infection.Respiratory syncytial virus induces phosphorylation of mTOR at ser2448 in CD8 T cells from nasal washes of infected infants.Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.Respiratory syncytial virus elicits enriched CD8+ T lymphocyte responses in lung compared with blood in African green monkeys.An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.Age-related declines in immune response in a wild mammal are unrelated to immune cell telomere length.Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults.
P2860
Q26748856-29E1B2FC-4688-4236-AE20-149A2BCE769FQ27312129-9F38DB45-0F7A-4468-B089-EE153FA9D45AQ33601830-D7A2A4B3-51B1-4744-87A6-9EF5E881D196Q33837530-B41D8272-1469-4262-BDD7-8400362F2E88Q34059447-B1314765-795E-4611-9B8F-34DD20112FC4Q34208395-881F9D76-1DB9-4E8C-B75F-0D9BE94BA3E3Q34396689-6F92B8F2-866D-40E4-A8DA-911590B917CEQ34699685-DE55E09B-7E45-4034-A852-3DB19A756534Q34964939-56B10984-52F9-408A-A3C6-D261D717A852Q35099663-066499B4-31B0-47E8-A400-BCC9ADF76759Q35635434-AD16F218-7099-4427-9B39-AE9B7CB15422Q35819905-2BAF3BD6-FE57-464A-93F7-CDAFDF75F2E9Q36029171-40437077-F3D2-4281-91B3-9BEAB22C0214Q36347381-BEEC3F8B-4469-41ED-9126-032C2466B758Q36353767-2EEEFF0B-1B72-4197-8E5F-3F5DDC104827Q37587807-F4612F1B-406C-4A9E-8422-F2029134F462Q38140040-4CB56D82-8DD0-4E6E-A6C9-5038C1296727Q38604787-656E5429-6E88-42A3-8B38-77A1B148A8B1Q38660842-DDE2BFD1-8C17-4248-8750-A3ECD75CB9F9Q39027049-82BB9CD7-4052-4A86-9E94-6AF7CAC2DCF5Q39127064-141C91C6-0AD4-460F-B841-AA1B0A8B5124Q40134310-696FAFD2-0338-4423-8023-05DDAD9E9931Q40244825-609E960F-41F7-4B36-8052-C0CF35BD75BBQ40388370-BEBDC531-1F7F-46C6-9B62-CF564A9731B6Q40465877-D15EBE29-9C06-46C8-AE86-0EC9339CF6FFQ41055844-49D5E042-4E37-4546-A884-C1963310BDA1Q45324151-4CDA3C94-BC8D-4243-8819-0F933A40E364Q45325049-63057E8C-15A4-4C33-AC5D-6D3504CC763FQ45326384-6D7A2DB7-AEA6-4912-8049-85A211190E4DQ51306275-71427CD7-38D7-446A-8958-006C311B6C0CQ55491624-BB9B7A0F-6CB3-41AD-89FE-B474361B78F2
P2860
Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Adults 65 years old and older ...... syncytial virus fusion protein
@ast
Adults 65 years old and older ...... syncytial virus fusion protein
@en
type
label
Adults 65 years old and older ...... syncytial virus fusion protein
@ast
Adults 65 years old and older ...... syncytial virus fusion protein
@en
prefLabel
Adults 65 years old and older ...... syncytial virus fusion protein
@ast
Adults 65 years old and older ...... syncytial virus fusion protein
@en
P2093
P2860
P356
P1476
Adults 65 years old and older ...... syncytial virus fusion protein
@en
P2093
Anu Cherukuri
Fengrong Zuo
Jennifer Woo
Kathryn Patton
Mark T Esser
Robert A Gasser
Roderick S Tang
P2860
P304
P356
10.1128/CVI.00580-12
P577
2012-12-12T00:00:00Z